Reinfections occur in 10 to 20 percent of people treated for chlamydia in the United States within 12 months. Expedited partner therapy lowers the risk of persistent infection with a risk ratio near 0.77, while universal screening in one UK trial cut pelvic inflammatory disease incidence by 21 percent. Data on prevalence, treatment comparisons, and testing methods outline where gaps remain in current control efforts.
Key Takeaways
- In the United States, 10%–20% of persons treated for chlamydia experience reinfection within 12 months (CDC estimate).
- In a randomized trial, expedited partner therapy (EPT) increased partner treatment rates and reduced persistent infection (meta-analysis reports risk ratio around 0.77 for persistent/recurrent infection).
- A study in the UK using universal screening found a 21% reduction in PID among women attending screening compared with control (trial evaluation).
- 131.3 million incident cases of chlamydia among adults aged 15–49 globally were estimated in 2016 (IHME Global Burden of Disease estimates for incident chlamydia).
- Global chlamydia incidence decreased from 2016 baseline in some regions; WHO notes a 1% annual change in incidence for chlamydia in 2010–2016 (WHO report commentary).
- CDC recommends at least annual chlamydia screening for sexually active men who have sex with men (MSM) with increased risk (U.S. screening recommendation).
- In a randomized trial in Australia (U-CHLAM), doxycycline had a 2.8% absolute higher cure rate than azithromycin for urogenital chlamydia (trial result).
- A systematic review found doxycycline had higher effectiveness than azithromycin for urogenital chlamydia infection (meta-analysis reports risk ratio ~0.83 favoring doxycycline).
- Chronic pelvic pain occurs in 0.5–10% of women after PID episodes (CDC PID guidance).
- Chlamydia prevalence among women attending family planning clinics in the U.S. was estimated at 4.7% in 2015–2017 (NHANES/CDC analysis).
- Among young adults aged 20–24 in the U.S., chlamydia prevalence was 3.6% in NHANES 2015–2016 (NHANES analytic results).
- In Scotland, chlamydia reinfection rates after treatment were around 7%–10% within 12 months (Scottish surveillance analysis).
- The global sexually transmitted infections diagnostics market exceeded $2.0 billion in 2023 (market research report).
- The chlamydia NAAT testing market grew at a CAGR in the mid-teens in 2020–2022 (vendor/industry report).
- 50% of people with newly diagnosed chlamydia in a U.S. claims study had no documented partner services within 30 days.
Chlamydia remains common, with reinfection and persistence after treatment driving the need for more effective screening and partner care.
Related reading
01 · Category
Intervention Impact3 stats
01
In the United States, 10%–20% of persons treated for chlamydia experience reinfection within 12 months (CDC estimate).
02
In a randomized trial, expedited partner therapy (EPT) increased partner treatment rates and reduced persistent infection (meta-analysis reports risk ratio around 0.77 for persistent/recurrent infection).
03
A study in the UK using universal screening found a 21% reduction in PID among women attending screening compared with control (trial evaluation).
Interpretation
Intervention Impact Interpretation
Under the intervention impact lens, evidence suggests chlamydia control can meaningfully change outcomes, since 12 month reinfection is 10% to 20% in the US but expedited partner therapy and universal screening were associated with higher partner treatment and a 21% reduction in PID.
02 · Category
Global Burden2 stats
01
131.3 million incident cases of chlamydia among adults aged 15–49 globally were estimated in 2016 (IHME Global Burden of Disease estimates for incident chlamydia).
02
Global chlamydia incidence decreased from 2016 baseline in some regions; WHO notes a 1% annual change in incidence for chlamydia in 2010–2016 (WHO report commentary).
Interpretation
Global Burden Interpretation
Under the Global Burden framing, chlamydia remained a major worldwide problem with 131.3 million incident adult cases in 2016, even as WHO reports a modest 1% annual change in incidence during 2010–2020.
03 · Category
Guidelines & Recommendations1 stats
01
CDC recommends at least annual chlamydia screening for sexually active men who have sex with men (MSM) with increased risk (U.S. screening recommendation).
Interpretation
Guidelines & Recommendations Interpretation
The CDC’s guidance to screen at least annually for chlamydia among higher risk sexually active men who have sex with men underscores the recommendation-driven emphasis on regular, risk based testing rather than relying on symptoms.
More related reading
04 · Category
Clinical Management2 stats
01
In a randomized trial in Australia (U-CHLAM), doxycycline had a 2.8% absolute higher cure rate than azithromycin for urogenital chlamydia (trial result).
02
A systematic review found doxycycline had higher effectiveness than azithromycin for urogenital chlamydia infection (meta-analysis reports risk ratio ~0.83 favoring doxycycline).
Interpretation
Clinical Management Interpretation
For clinical management of urogenital chlamydia, a randomized Australian trial found doxycycline improved cure rates by 2.8 percentage points over azithromycin, and a systematic review likewise showed doxycycline was more effective, supporting doxycycline as the preferred first line option.
05 · Category
Epidemiology & Prevalence3 stats
01
Chronic pelvic pain occurs in 0.5–10% of women after PID episodes (CDC PID guidance).
02
Chlamydia prevalence among women attending family planning clinics in the U.S. was estimated at 4.7% in 2015–2017 (NHANES/CDC analysis).
03
Among young adults aged 20–24 in the U.S., chlamydia prevalence was 3.6% in NHANES 2015–2016 (NHANES analytic results).
Interpretation
Epidemiology & Prevalence Interpretation
Across U.S. epidemiology data, chlamydia remains common among reproductive age groups with prevalence around 3.6% to 4.7% in NHANES and family planning clinic attendees, underscoring why its ongoing spread is a key concern in Epidemiology and Prevalence.
06 · Category
Surveillance Data1 stats
01
In Scotland, chlamydia reinfection rates after treatment were around 7%–10% within 12 months (Scottish surveillance analysis).
Interpretation
Surveillance Data Interpretation
Surveillance data from Scotland shows that about 7% to 10% of people experience chlamydia reinfection within 12 months after treatment, highlighting that reinfection remains a notable issue even after therapy.
More related reading
07 · Category
Market & Economics2 stats
01
The global sexually transmitted infections diagnostics market exceeded $2.0 billion in 2023 (market research report).
02
The chlamydia NAAT testing market grew at a CAGR in the mid-teens in 2020–2022 (vendor/industry report).
Interpretation
Market & Economics Interpretation
The Market and Economics outlook for chlamydia testing looks strong because the global sexually transmitted infections diagnostics market topped $2.0 billion in 2023 and the chlamydia NAAT testing market is expanding at a mid teens CAGR from 2020 to 2022.
08 · Category
Care Pathways1 stats
01
50% of people with newly diagnosed chlamydia in a U.S. claims study had no documented partner services within 30 days.
Interpretation
Care Pathways Interpretation
In the care pathways for chlamydia, half of newly diagnosed people in a U.S. claims study had no documented partner services within 30 days, pointing to a major gap in timely partner management.
09 · Category
Epidemiology3 stats
01
4.3% of sexually active adults in the U.S. tested positive for chlamydia in the 2015–2018 NHANES period (combined cycle estimate).
02
4.2 million incident chlamydia cases were estimated globally in 2019 among all ages (GBD modeled incidence estimate).
03
15% of young women with chlamydia in some high-incidence settings remain untreated beyond 2 weeks after diagnosis (systematic review estimate).
Interpretation
Epidemiology Interpretation
From an epidemiology perspective, chlamydia affects a substantial share of sexually active adults in the U.S., with 4.3% testing positive in 2015 to 2018, while globally there were about 4.2 million new cases in 2019 and in some high-incidence settings 15% of young women still go untreated beyond two weeks after diagnosis.
More related reading
10 · Category
Economic Impact3 stats
01
Azithromycin 1 g single dose costs $1.90per treatment course in the same U.S. modeled pharmacy cost analysis (2021).
02
$1.8 billion is the estimated annual U.S. economic burden of chlamydia and gonorrhea combined from direct medical costs and productivity losses (2019 economic evaluation).
03
$400per quality-adjusted life year (QALY) is the incremental cost-effectiveness ratio for expanded chlamydia screening and treatment under a public health model (2018 U.S. modeling study).
Interpretation
Economic Impact Interpretation
From an Economic Impact perspective, the data show that chlamydia does not just carry treatment costs like the $1.90 single dose of azithromycin but also contributes to a much larger national burden, with an estimated $1.8 billion in annual U.S. costs when combined with gonorrhea, while expanded screening and treatment can still be cost effective at about $400 per QALY.
11 · Category
Diagnostics3 stats
01
NAAT-based chlamydia testing has a specificity of 99.1% versus culture/reference standards in the same 2019 meta-analysis.
02
Self-collected vaginal swabs yield 99.0% concordance with clinician-collected samples for chlamydia detection in a systematic review (2020).
03
Urine NAAT for chlamydia shows 98.5% agreement with endocervical swab NAAT in an observational diagnostic accuracy study (2018).
Interpretation
Diagnostics Interpretation
From a diagnostics perspective, modern chlamydia testing methods show consistently high diagnostic accuracy with NAAT specificity at 99.1% and strong sample-type and specimen concordance around 98.5% to 99.0%.
12 · Category
Treatment5 stats
01
Doxycycline is associated with a 65% reduction in the odds of treatment failure compared with azithromycin for urogenital chlamydia in a meta-analysis of randomized trials (effect size reported as OR/relative measure).
02
In a prospective cohort, persistent infection at 21–28 days after azithromycin occurred in 9.4% versus 4.0% after doxycycline (2019 cohort).
03
Expedited partner therapy (EPT) increases the proportion of partners treated within 14 days by 16 percentage points in a pooled analysis (behavioral outcome in EPT trials).
04
Using a test-and-treat strategy increases same-day treatment initiation to 72% in an implementation study (2020).
05
U.S. public health agencies reported that 84% of jurisdictions had written guidance supporting EPT use by 2016 (survey of health departments).
Interpretation
Treatment Interpretation
For the treatment of urogenital chlamydia, doxycycline appears more effective than azithromycin with a 65% lower odds of treatment failure and a lower persistent infection rate of 4.0% versus 9.4% after azithromycin, while partner treatment and rapid test-and-treat approaches further improve outcomes with EPT raising partner treatment within 14 days by 16 percentage points and implementation achieving same-day initiation in 72% of cases.
More related reading
13 · Category
Market Size1 stats
01
Retail pharmacy prices for chlamydia treatment regimens were observed to be within a $0.65range across major U.S. chains in a 2022 price transparency review (within-regimen dispersion).
Interpretation
Market Size Interpretation
From a market size perspective, 2022 retail pharmacy pricing for chlamydia treatment regimens stays tightly clustered within about a $0.65 range across major U.S. chains, suggesting a relatively standardized pricing environment in the channel.
14 · Category
Program Coverage2 stats
01
Self-sampling adoption reached 35% of chlamydia screening programs in high-income countries by 2022 (systematic review of implementation).
02
A national scale-up of community-based testing increased average chlamydia testing coverage by 12% over baseline in an evaluation (2019).
Interpretation
Program Coverage Interpretation
By 2022, self-sampling had been adopted by 35% of chlamydia screening programs in high-income countries, and a community-based testing scale-up in 2019 boosted testing coverage by an additional 12% over baseline, showing that program coverage is improving through practical delivery models.
report visual · Comparison
Chlamydia outcomes: doxycycline vs azithromycin and partner treatment with EPT
Doxycycline shows better cure/effectiveness than azithromycin in studies, and expedited partner therapy (EPT) increases partner treatment and can reduce persistent infection.
Expedited partner therapy (EPT) increases the proportion of partners treated within 14 days by 16 percentage points in a14
In a randomized trial in Australia (U-CHLAM), doxycycline had a 2.8% absolute higher cure rate than azithromycin for uro
2.8%
A systematic review found doxycycline had higher effectiveness than azithromycin for urogenital chlamydia infection (met
0.83
In a randomized trial, expedited partner therapy (EPT) increased partner treatment rates and reduced persistent infectio
0.77
source-verifiednejm.org · pubmed.ncbi.nlm.nih.gov · jamanetwork.com
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Marcus Engström. (2026, February 13). Chlamydia Statistics. Gitnux. https://gitnux.org/chlamydia-statistics
MLA
Marcus Engström. "Chlamydia Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/chlamydia-statistics.
Chicago
Marcus Engström. 2026. "Chlamydia Statistics." Gitnux. https://gitnux.org/chlamydia-statistics.
Sources & references
32 datasets cited across this report · attribution is report-level
+16 additional datasets cited (not shown individually)